202 related articles for article (PubMed ID: 34793830)
1. Anti-Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis Network.
Leclercq M; Andrillon A; Maalouf G; Sève P; Bielefeld P; Gueudry J; Sené T; Moulinet T; Rouvière B; Sène D; Desbois AC; Domont F; Touhami S; El Chamieh C; Cacoub P; Bodaghi B; Biard L; Saadoun D
Ophthalmology; 2022 May; 129(5):520-529. PubMed ID: 34793830
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema.
Mesquida M; Molins B; Llorenç V; Sainz de la Maza M; Adán A
Ophthalmology; 2014 Dec; 121(12):2380-6. PubMed ID: 25204610
[TBL] [Abstract][Full Text] [Related]
3. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients.
Barroso-García N; Atienza-Mateo B; Ferraz-Amaro I; Prieto-Peña D; Beltrán E; Adán A; Hernández-Garfella M; Martínez-Costa L; Cordero-Coma M; Díaz-Llopis M; Herreras JM; Maíz-Alonso O; Torre-Salaberri I; De Vicente-Delmás A; Díaz-Valle D; Atanes-Sandoval A; Francisco F; Insua S; Sánchez J; Almodóvar-González R; Jiménez-Sosa A; Ruiz-Moreno O; Gandía-Martínez M; Nolla JM; Calvo-Río V; Castañeda S; González-Gay MA; Blanco R
Semin Arthritis Rheum; 2023 Feb; 58():152153. PubMed ID: 36549244
[TBL] [Abstract][Full Text] [Related]
4. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients.
Vegas-Revenga N; Calvo-Río V; Mesquida M; Adán A; Hernández MV; Beltrán E; Valls Pascual E; Díaz-Valle D; Díaz-Cordovés G; Hernandez-Garfella M; Martínez-Costa L; Calvo I; Atanes A; Linares LF; Modesto C; González-Vela C; Demetrio-Pablo R; Aurrecoechea E; Cordero M; Domínguez-Casas LC; Atienza-Mateo B; Martín-Varillas JL; Loricera J; Palmou-Fontana N; Hernández JL; González-Gay MA; Blanco R
Am J Ophthalmol; 2019 Apr; 200():85-94. PubMed ID: 30660771
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab in Uveitic Macular Edema Refractory to Previous Immunomodulatory Treatment.
Deuter CME; Zierhut M; Igney-Oertel A; Xenitidis T; Feidt A; Sobolewska B; Stuebiger N; Doycheva D
Ocul Immunol Inflamm; 2017 Apr; 25(2):215-220. PubMed ID: 26731514
[TBL] [Abstract][Full Text] [Related]
6. Long-term Efficacy of TNF-alpha Inhibitors on Persistent Uveitic Macular Edema: A Swiss Multicenter Cohort Study.
Bograd A; Fuchs D; Bächtiger J; Pfister IB; Spindler J; Hoogewoud F; Gugleta K; Böni C; Guex-Crosier Y; Garweg JG; Tappeiner C
Ocul Immunol Inflamm; 2023 Jul; 31(5):981-988. PubMed ID: 35588311
[TBL] [Abstract][Full Text] [Related]
7. Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients.
Maalouf G; Andrillon A; Leclercq M; Sève P; Bielefeld P; Gueudry J; Sené T; Titah C; Moulinet T; Rouvière B; Sène D; Desbois AC; Domont F; Touhami S; Thibault T; Chamieh CE; Cacoub P; Kodjikian L; Biard L; Bodaghi B; Saadoun D
Am J Ophthalmol; 2022 Jun; 238():173-180. PubMed ID: 35172172
[TBL] [Abstract][Full Text] [Related]
8. Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network.
Vallet H; Seve P; Biard L; Baptiste Fraison J; Bielefeld P; Perard L; Bienvenu B; Abad S; Rigolet A; Deroux A; Sene D; Perlat A; Marie I; Feurer E; Hachulla E; Fain O; Clavel G; Riviere S; Bouche PA; Gueudry J; Pugnet G; Le Hoang P; Resche Rigon M; Cacoub P; Bodaghi B; Saadoun D;
Arthritis Rheumatol; 2016 Jun; 68(6):1522-30. PubMed ID: 27015607
[TBL] [Abstract][Full Text] [Related]
9. TWENTY-FOUR MONTH FOLLOW-UP OF TOCILIZUMAB THERAPY FOR REFRACTORY UVEITIS-RELATED MACULAR EDEMA.
Mesquida M; Molins B; Llorenç V; Hernández MV; Espinosa G; Sainz de la Maza M; Adán A
Retina; 2018 Jul; 38(7):1361-1370. PubMed ID: 28520640
[TBL] [Abstract][Full Text] [Related]
10. Comparison of conventional immunosuppressive drugs versus anti-TNF-α agents in non-infectious non-anterior uveitis.
Leclercq M; Langlois V; Girszyn N; Le Besnerais M; Benhamou Y; Levesque H; Muraine M; Gueudry J
J Autoimmun; 2020 Sep; 113():102481. PubMed ID: 32586650
[TBL] [Abstract][Full Text] [Related]
11. Re: Leclercq et al.: Anti-tumor necrosis factor-α versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the French Uveitis Network (Ophthalmology. 2022;129:520-529).
Pépin F; Niederer RL
Ophthalmology; 2022 Jul; 129(7):e77. PubMed ID: 35346510
[No Abstract] [Full Text] [Related]
12. Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis.
Barry RJ; Tallouzi MO; Bucknall N; Mathers JM; Murray PI; Calvert MJ; Moore DJ; Denniston AK
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012577. PubMed ID: 30562409
[TBL] [Abstract][Full Text] [Related]
13. Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis.
Schaap-Fogler M; Amer R; Friling R; Priel E; Kramer M
Graefes Arch Clin Exp Ophthalmol; 2014 Apr; 252(4):633-40. PubMed ID: 24366669
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Anti-IL6-Receptor Tocilizumab in Refractory Cystoid Macular Edema of Birdshot Retinochoroidopathy Report of Two Cases and Literature Review.
Calvo-Río V; Blanco R; Santos-Gómez M; Díaz-Valle D; Pato E; Loricera J; González-Vela MC; Demetrio-Pablo R; Hernández JL; González-Gay MA
Ocul Immunol Inflamm; 2017 Oct; 25(5):604-609. PubMed ID: 27726475
[TBL] [Abstract][Full Text] [Related]
15. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients.
Calvo-Río V; Santos-Gómez M; Calvo I; González-Fernández MI; López-Montesinos B; Mesquida M; Adán A; Hernández MV; Maíz O; Atanes A; Bravo B; Modesto C; Díaz-Cordovés G; Palmou-Fontana N; Loricera J; González-Vela MC; Demetrio-Pablo R; Hernández JL; González-Gay MA; Blanco R
Arthritis Rheumatol; 2017 Mar; 69(3):668-675. PubMed ID: 27696756
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
[TBL] [Abstract][Full Text] [Related]
17. intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group.
Wu L; Hernandez-Bogantes E; Roca JA; Arevalo JF; Barraza K; Lasave AF
Retina; 2011 Feb; 31(2):298-303. PubMed ID: 21099452
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab treatment for refractory uveitis-related cystoid macular edema.
Adán A; Mesquida M; Llorenç V; Espinosa G; Molins B; Hernández MV; Pelegrín L
Graefes Arch Clin Exp Ophthalmol; 2013 Nov; 251(11):2627-32. PubMed ID: 23893042
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab for the treatment of birdshot uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy: two cases report and literature review.
Leclercq M; Le Besnerais M; Langlois V; Girszyn N; Benhamou Y; Ngo C; Levesque H; Muraine M; Gueudry J
Clin Rheumatol; 2018 Mar; 37(3):849-853. PubMed ID: 29397459
[TBL] [Abstract][Full Text] [Related]
20. INFLIXIMAB and ADALIMUMAB in Uveitic Macular Edema.
Lejoyeux R; Diwo E; Vallet H; Saadoun D; Tezenas du Montcel S; Bodaghi B; LeHoang P; Fardeau C
Ocul Immunol Inflamm; 2018; 26(7):991-996. PubMed ID: 30096013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
